CG Oncology (CGON) Share-based Compensation (2023 - 2026)

CG Oncology's Share-based Compensation history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Share-based Compensation fell 74.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 91.35% YoY) and the FY2025 annual result came in at $26.7 million, up 133.96% from the prior year.
• Share-based Compensation was $1.3 million for Q1 2026 at CG Oncology, down from $7.2 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.3 million in Q3 2025 and bottomed at $177000.0 in Q2 2023.
• A 4-year average of $3.1 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 1168.93% — and 2026, when it slumped 74.76%.
• CG Oncology's Share-based Compensation stood at $778000.0 in 2023, then jumped by 541.39% to $5.0 million in 2024, then surged by 44.03% to $7.2 million in 2025, then sank by 81.91% to $1.3 million in 2026.
• Business Quant data shows CGON's Share-based Compensation at $1.3 million in Q1 2026, $7.2 million in Q4 2025, and $7.3 million in Q3 2025.